Investment Analysts’ Recent Ratings Changes for Exelixis (EXEL)

Exelixis (NASDAQ: EXEL) has recently received a number of price target changes and ratings updates:

• 8/11/2026 – Exelixis was upgraded by Weiss Ratings from “buy (b)” to “buy (a-)”.
• 8/8/2026 – Exelixis was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/6/2026 – Exelixis had its price target lowered by Truist Financial Corporation from $56.00 to $52.00. They now have a “hold” rating on the stock.
• 8/6/2026 – Exelixis was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $52.00 price target on the stock.
• 8/6/2026 – Exelixis had its price target raised by Stifel Nicolaus from $47.00 to $51.00. They now have a “hold” rating on the stock.
• 8/3/2026 – Exelixis was given a new $55.00 price target by UBS Group AG.
• 8/3/2026 – Exelixis was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/24/2026 – Exelixis was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 7/23/2026 – Exelixis had its price target raised by Morgan Stanley from $50.00 to $53.00. They now have an “equal weight” rating on the stock.
• 7/22/2026 – Exelixis had its “market outperform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Exelixis had its price target raised by Barclays PLC from $45.00 to $49.00. They now have an “equal weight” rating on the stock.
• 7/13/2026 – Exelixis had its price target raised by Wells Fargo & Company from $40.00 to $49.00. They now have an “equal weight” rating on the stock.
• 7/8/2026 – Exelixis was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 7/7/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $43.00 to $46.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Exelixis had its price target raised by Truist Financial Corporation from $54.00 to $56.00. They now have a “hold” rating on the stock.
• 7/2/2026 – Exelixis had its “buy” rating reaffirmed by UBS Group AG.
• 7/2/2026 – Exelixis had its price target raised by UBS Group AG from $43.00 to $52.00. They now have a “neutral” rating on the stock.
• 7/2/2026 – Exelixis had its “buy” rating reaffirmed by HC Wainwright. They now have a $56.00 price target on the stock.
• 6/25/2026 – Exelixis was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $54.00 price target on the stock, up from $51.00.
• 6/24/2026 – Exelixis had its price target raised by Citizens Jmp from $50.00 to $55.00. They now have a “market outperform” rating on the stock.
• 6/22/2026 – Exelixis had its “positive” rating reaffirmed by Morgan Stanley.

Insider Activity

In other news, EVP Dana Aftab sold 43,451 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total value of $2,187,757.85. Following the transaction, the executive vice president directly owned 594,741 shares in the company, valued at approximately $29,945,209.35. This represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mary C. Beckerle sold 9,812 shares of Exelixis stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the sale, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. The trade was a 37.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 140,636 shares of company stock valued at $7,081,743. Insiders own 2.60% of the company’s stock.

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.